MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Short-Lived Isotope Opens New Possibilities for Cancer Treatment

By MedImaging International staff writers
Posted on 08 Sep 2016
Print article
Image: The SLAC National Accelerator Laboratory (Photo courtesy of SLAC).
Image: The SLAC National Accelerator Laboratory (Photo courtesy of SLAC).
A radioisotope of the element actinium is a promising agent for targeted-α therapy to destroy malignant cells, while minimizing the damage to healthy surrounding tissue.

Developed by researchers at Los Alamos National Laboratory (LANL; NM, USA), and in collaboration with the Stanford Linear Accelerator Center (SLAC) Laboratory (SLAC; Menlo Park, CA, USA), targeted-α therapy is based on the radioisotope actinium-225, which has a relatively short half-life of 10 days and emits powerful alpha particles as it decays to stable bismuth. But targeted-α therapy can only become a reliable cancer treatment if actinium securely binds to a chelator, as the radioisotope is very toxic to healthy tissue.

In an attempt to clarify the limited understanding of actinium chemistry, the researchers used X-ray absorption spectroscopy and molecular dynamics density functional theory to investigate actinium coordination chemistry. They were able to determine information about chemical bonds formed by actinium, including what binds to the element, how many atoms are present, and the distances between them. The researchers will now attempt to engineer a chelator carrier molecule that could safely transport actinium-225 through the body to tumor cells. The study was published on August 17, 2016, in Nature Communications.

“Imagine if someone gave you the element iron and nothing was known. That’s almost the same place we were in with actinium, as far as macroscopic chemistry goes. The Manhattan Project scientists used film to see the X-rays released off the sample,” said study co-author Stosh Kozimor, PhD, an isotope chemist at Los Alamos, “but the radioactivity from actinium darkened the film before they could make meaningful measurements. They were only able to get a fingerprint of the actinium compounds that were suggestive of what formed. Beyond that, there isn’t much information in those measurements.”

Actinium (Ac), discovered in 1899, is a radioactive chemical element with the atomic number 89. It was the first non-primordial radioactive element to be isolated. A soft, silvery-white metal, it reacts rapidly with oxygen and moisture in air, forming a white coating of actinium oxide that prevents further oxidation. One ton of natural uranium in ore contains about 0.2 milligrams of actinium-227. Owing to its scarcity, high price, and radioactivity, actinium has no significant industrial use.

Related Links:
Los Alamos National Laboratory
Stanford Linear Accelerator Center Laboratory
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Illuminator
Trimline Basic
Brachytherapy Planning System
Oncentra Brachy
PACS Workstation
CHILI Web Viewer

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more